Prognostic factors in the early phase of acute encephalopathy

2018 ◽  
Vol 60 (3) ◽  
pp. 270-275
Author(s):  
Chizu Oba ◽  
Mitsuru Kashiwagi ◽  
Takuya Tanabe ◽  
Shohei Nomura ◽  
Motoko Ogino ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Early Phase ◽  
Acute Encephalopathy

Prognostic factors in acute encephalopathy with reduced subcortical diffusion

2012 ◽  
Vol 34 (8) ◽  
pp. 632-639 ◽  
Author(s):  
Naoko Hayashi ◽  
Akihisa Okumura ◽  
Tetsuo Kubota ◽  
Takeshi Tsuji ◽  
Hiroyuki Kidokoro ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Encephalopathy

Prognostic factors for acute encephalopathy with bright tree appearance

2015 ◽  
Vol 37 (2) ◽  
pp. 191-199 ◽  
Author(s):  
Junji Azuma ◽  
Shin Nabatame ◽  
Sayaka Nakano ◽  
Yoshiko Iwatani ◽  
Yukihiro Kitai ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Encephalopathy

Prognostic factors for survival in early-phase trials in hematology.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e13094-e13094
Author(s):  
R. Jamal ◽  
G. Hristova ◽  
C. Holcroft ◽  
S. E. Assouline
Keyword(s):  
Prognostic Factors ◽  
Early Phase ◽  
Early Phase Trials

Prognostic Factors Among Children With Acute Encephalitis/Encephalopathy Associated With Viral and Other Pathogens

2020 ◽  
Author(s):  
Takeshi Hatachi ◽  
Nobuaki Michihata ◽  
Yu Inata ◽  
Muneyuki Takeuchi ◽  
Hiroki Matsui ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Virus Infection ◽  
Early Phase ◽  
Tube Feeding ◽  
Influenza Virus Infection ◽  
Patient Characteristics ◽  
Unfavorable Outcome ◽  
Therapeutic Interventions ◽  
Hospital Death ◽  
Acute Encephalitis

Abstract Background Acute encephalitis/encephalopathy (AE) associated with viral and other pathogens leads to neurological sequelae and mortality. Knowing the prognostic factors is therefore important for immediate interventions. We examined early-phase unfavorable prognostic factors among children with AE using a nationwide database. Methods We performed a retrospective cohort study using the Diagnosis Procedure Combination database, which includes approximately half of acute-care inpatients across Japan. We enrolled children aged ≤ 18 years who were hospitalized for AE and discharged from April 2010 to March 2018. The composite unfavorable outcome included the following at discharge: in-hospital death, tracheostomy, enteral tube feeding, and physical rehabilitation. Unfavorable prognostic factors were assessed using a multivariable Poisson regression model including patient characteristics, associated pathogens, and interventions within 2 days of admission adjusting for within-hospital clustering. Results This study included 9386 children with AE (median age, 3 years). A total of 241 (2.6%) in-hospital deaths occurred, and 2027 (21.6%) patients had the composite unfavorable outcome. Significant unfavorable prognostic factors were age 12–18 years, congenital anomalies, epilepsy, and Japan Coma Scale score of 100–300 at admission (ie, worse levels of consciousness). In contrast, herpes simplex virus infection and influenza virus infection were associated with favorable outcomes. Conclusions We identified early-phase (within 2 days of admission) unfavorable prognostic factors among children with AE. These findings will help identify patients who may benefit from early aggressive therapeutic interventions.

Diagnostic and prognostic factors for acute encephalopathy

2016 ◽  
Vol 58 (11) ◽  
pp. 1188-1192 ◽  
Author(s):  
Yukiko Motojima ◽  
Michiaki Nagura ◽  
Yoshitaka Asano ◽  
Hiroshi Arakawa ◽  
Eiko Takada ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Encephalopathy

Prognostic factors in RET dependent cancers treateded with RET inhibitors in early phase clinical trials.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 3117-3117
Author(s):  
Max Gordon ◽  
Jason Roszik ◽  
Maria E. Cabanillas ◽  
Mimi I-Nan Hu ◽  
Naifa Lamki Busaidy ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Factors ◽  
Brain Metastases ◽  
Survival Data ◽  
Early Phase ◽  
Objective Response ◽  
Prognostic Scores ◽  
Cancer Center ◽  
P Value ◽  
M918t Mutation

3117 Background: Activation of the RET proto-oncogene has been identified in multiple cancer types, for example, gene rearrangements in non-small cell lung cancer (NSCLC) and papillary thyroid cancer (PTC) and activating mutations in medullary thyroid cancer (MTC), amongst others. The recent FDA approval of two highly selective RET inhibitors, selpercatinib and pralsetinib has changed the treatment paradigm of RET-driven cancers, but the significance of historical prognostic factors is unknown. Herein, we analyzed the outcomes of patients with RET-altered cancers enrolled in phase I trials and assess the utility of prognostic scores. Methods: A retrospective analysis was performed of patients treated with selective RET inhibitors at the MD Anderson Cancer Center (MDACC). Baseline clinical factors and survival data were assessed. Overall and progression free survival (OS and PFS) were estimated using the Kaplan-Meier method and multivariable Cox models were constructed. For all a p-value of < 0.05 was consider significant. Results: Among 126 patients, median age was 58 years (range, 15-82), most with ECOG 0-1 (n = 124). RET-mutant MTC was most frequent (n = 81), followed by RET fusion-positive NSCLC (n = 30) and RET fusion positive thyroid cancer (n = 9). RET fusion partners were KIF5B (n = 17), CCD6 (n = 12) and NCOA4 (n = 7). RET M918T mutation was the most frequent (n = 50, 63%). Most patients were treated in the relapsed/refractory (R/R) setting (n = 85) and received a median of 1 prior line of therapy (range, 0-11). Median follow up was 20 months (range, 1-43). The estimated median PFS and OS were 24 and 35 months, respectively. Overall objective response rate was 64% (81/126), 2 complete response, 79 partial response, 32 had stable disease (25%) and 13 had progressive disease (PD). The following were associated with shorter PFS and OS: age ≥50 years (p < 0.05), albumin < 4 g/dL (p < 0.01), brain metastases (p < 0.0001), hemoglobin < 12 g/dL ( < 0.05), LDH > normal (p < 0.05), WBC ≥8 (p < 0.01), PD (p < 0.0001) and NSCLC (p < 0.01). The M918T mutation and ECOG > 0 were associated with shorter OS but not PFS (p < 0.05). > 3 metastatic sites and R/R disease were associated with inferior PFS (p = 0.04 and p = 0.01, respectively) but not OS. The Royal Marsden Hospital (RMH) and MDACC prognostic scores were significantly associated with PFS and OS (p < 0.01). In multivariable models including all variables significantly associated with PFS and OS (excluding LDH as this was only tested in 58 patients) albumin < 4 (HR 6.10, p = 0.013), brain metastases (HR 4.90, p = 0.027) and WBC ≥8 (HR 4.67, p = 0.031) were associated with inferior OS. NSCLC was significantly associated with inferior PFS (HR 5.45, p = 0.02). Conclusions: The RMH and MDACC prognostic scores predict OS in RET-aberrant cancers treated on early phase trials. Low albumin, WBC > 8 and brain metastases are significantly associated with inferior survival.

Early prognostic factors for acute encephalopathy with reduced subcortical diffusion

2018 ◽  
Vol 40 (8) ◽  
pp. 707-713 ◽  
Author(s):  
Tetsuhiro Fukuyama ◽  
Shouko Yamauchi ◽  
Shunsuke Amagasa ◽  
Yuka Hattori ◽  
Taku Sasaki ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Acute Encephalopathy
Sign in / Sign up

Export Citation Format

Share Document